associate professor li shiliang-全讯国际

contact information

• office:room 516, researching building 18

• email:

• office phone: 86 21 6425 0213

• office fax: 86 21 6425 0213

education

• 2016.06 ph.d. computational chemistry, school of pharmacy, east china university of science&technology, shanghai, p. r. china

• 2011.06b.e.  pharmaceutical engineering, school of pharmacy, east china university of science&technology, shanghai, p. r. china

professional experience

• 2018.11-nowassociate professor, school of pharmacy, east china university of science and technology

• 2016.07-2018.10postdoctoral research fellow, school of pharmacy, east china university of science and technology

research interests

• homology modeling, virtual screening, lead discovery & optimization

• target of off-target prediction

• ligand-receptor binding thermodynamic and kinetics study & molecular biology

• molecular polypharmacology study

• drug metabolism prediction

publication

1. shiliang li^#, chun qin^#, shichao cui^#, hongling xu, fangshu wu, jiawei wang, mingbo su, xiaoyu fang, dan li, qian jiao, ming zhang, chunmei xia, lili zhu, rui wang, jia li, hualiang jiang, zhenjiang zhao, jing-ya li, honglin li. discovery of a natural-product-derived preclinical candidate for once-weekly treatment of type 2 diabetes. j. med. chem., 2019. 62(5) :2348-2361.

2. qiannan li^#, tao zhang^#, shiliang li^#, linjiang tong, junyu li, zhicheng su, fang feng, deheng sun, yi tong, xiawang, zhenjiang zhao, lili zhu, jian ding, honglin li, hua xie, yufang xu. discovery of potent and non-covalent reversible egfr kinase inhibitors of egfr l858r/t790m/c797s. acs med. chem. lett., 2019. 10(6) : 869-873.

3. disha wang, zihao shen, lei jiang, wenjun liu, jie wang, shiliang li*, honglin li*. deep learning based drug metabolites prediction. front. pharmacol., 2019. doi:10.3389/fphar.2019.01586.

4. lili zhu, lei shan, junsheng zhu, li li, shiliang li, liyan wang, jiawei wang, shoude zhang, hongchang zhou, weidong zhang*, honglin li*. discovery of a natural fluorescent probe targeting the plasmodium falciparum cysteine protease falcipain-2. sci. china life sci., 2019. doi:10.1007/s11427-019-1581-2.

5. gaoqi he, bojie gong, jianqiang li, yiping song, shiliang li*, xingjian lu*. an improved receptor-based pharmacophore generation algorithm guided by atomic chemical characteristics and hybridization types. front. pharmacol., 2018. 9 : 1463.

6. guixiang yang^#, songlan ge, yanwu, jin huang, shiliang li*, rui wang*, lei ma*. design, synthesis and biological evaluation of 3-piperazinecarboxylate sarsasapogenin derivatives as potential multifunctional anti-alzheimer agents. eur. j. med. chem. 2018, 156, 206-215.

7. jiajia meng^#, shiliang li^#, xiaofeng liu, mingyue zheng, honglin li*. rd-metabolizer: an integrated and reaction types extensive approach to predict metabolic sites and metabolites of drug-like molecules. chem. cent. j., 2017. 11 : 65.

8. fanxun zeng^#, tiantian qi^#, chunyan li, tingfang li, honglin li, shiliang li*, lili zhu*, xiaoyong xu*. synthesis, structure-activity relationship and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase. medchemcomm., 2017. 8 : 1297-1302.

9. shiliang li^#, hongling xu^#, shichao cui^#, fangshu wu, youli zhang, mingbo su, yinghui gong, shaobing qiu, qian jiao, chun qin, jiwei shan, ming zhang, jiawei wang, qiao yin, minghao xu, xiaofeng liu, rui wang, lili zhu, jia li, yufang xu, hualiang jiang, zhenjiang zhao*, jingya li*, honglin li*. discovery and rational design of natural product-derived 2-phenyl-3,4-dihydro-2h-benzo[f]chromen-3-amine analogs as novel and potent dpp-4 inhibitors for the treatment of type 2 diabetes. j. med. chem. 2016, 59 (14), 6772-6790.

10. shiliang li, xiaojuan yu, chuanxin zou, jiayu gong, xiaofeng liu, honglin li*. are topological properties of drug targets based on protein-protein interaction network ready to predict potential drug targets?. comb. chem. high throughput screen., 2016. 2 : 109-120.

11. shiliang li, yuwei song, xiaofeng liu, honglin li*. a rapid python-based methodology for target-focused combinatorial library design. comb. chem. high throughput screen., 2016. 1 : 25-35.

12. wei zhou^#, shiliang li^#, weiqiang lu^#, jun yuan, yufang xu, honglin li, jin huang*, zhenjiang zhao*. isoindole-1,3-dione derivatives as rsk2 inhibitors: synthesis, molecular docking simulation and sar analysis. med. chem. commun., 2016. 7 : 292-296.

13. wenlin song^#, shiliang li^#, yi tong^#, jiawei wang, lina quan, zhuo chen, zhenjiang zhao, yufang xu, lili zhu*, xuhong qian*, honglin li*. structure-based design of potent human dihydroorotate dehydrogenase inhibitors as anticancer agents. med. chem. commun.2016, 7 (7), 1441-1448.

14. shiliang li^#, guoqin luan^#, xiaoli ren^#, wenlin song, liuxin xu, minghao xu, junsheng zhu, dong dong, yanyan diao, xiaofeng liu, lili zhu, rui wang, zhenjiang zhao*, yufang xu*, honglin li*. rational design of benzylidenehydrazinyl-substituted thiazole derivatives as potent inhibitors of human dihydroorotate dehydrogenase with in vivo anti-arthritic activity. sci. rep., 2015. 5 : 14836.

15. shiliang li^#, yi zhou^#, weiqiang lu^#, ye zhong, jin huang, zhenjiang zhao, xiaofeng liu*, yufang xu*, honglin li*. identification of inhibitors against p90 ribosomal s6 kinase 2 (rsk2) through structure-based virtual screening with the inhibitor-constrained refined homology model. j. chem. inf. model., 2011. 51(11) : 2939-2947.

16. yanling wang, huan ge, disha wang, huan he, lu li, yanyan diao, zihao shen, lili zhu, shiliang li, zhenjiang zhao*, honglin li*. design and synthesis of a series of novel macrocycle janus kinase 2 inhibitors. chin. j. chem., 2019. 37 : 1259-1263.

17. jie wang, shiliang li, honglin li*. drug design of "undruggable" targets. chin. j. chem., 2019 37 : 501-512.

18. fanxun zeng, lina quan, guantian yang, tiantian qi, letian zhang, shiliang li, honglin li, lili zhu*, xiaoyong xu*. structural optimization and structure–activity relationship of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase. molecules, 2019. 24(15) : 2780.

19. wei xiao, disha wang, zihao shen, shiliang li, honglin li*. multi-body interactions in molecular docking program devised with key water molecules in protein binding sites. molecules, 2018. 23(9) : 2321-2342.

20. yanyan diao, jing jiang, shoude zhang,shiliang li, lei shan, jin huang, weidong zhang, honglin li*. discovery of natural products as novel and potent fxr antagonists by virtual screening. front. chem., 2018. 6 : 140.

21. shuping zheng; ying zhou; joy fleming; yafeng zhou; mengting zhang; shiliang li; honglin li; bingqi sun; wei liu; lijun bi. structural and genetic analysis of start superfamily protein msmeg_0129 from mycobacterium smegmatis. febs letters, 2018. 592(8) : 1445-1457.

22. xia wang, yihang shen, shiwei wang, shiliang li, weilin zhang, xiaofeng liu, luhua lai, jianfeng pei*, honglin li*. pharmmapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. nucleic acids res., 2017. 45 : w356-w360.

23. ertong li, yafeng wang, wenquan yu, zhigang lv, youmei peng, bingjie liu, shiliang li, wenzhe ho, qingduan wang, honglin li, junbiao chang* . synthesis and biological evaluation of a novel β-d-2′-deoxy-2′-α-fluoro-2′-β-c-(fluoromethyl)uridine phosphoramidate prodrug for the treatment of hepatitis c virus infection. eur. j. med. chem., 2017. 2018. 46(2) : 546-557.

24. xiuqin hu, disha wang, yi tong, linjiang tong, xia wang, lili zhu, hua xie, shiliang li, you yang* and yufang xu*. design, synthesis and evaluation of ribose-modified anilinopyrimidine derivatives as egfr tyrosine kinase inhibitors. front. chem., 2017. 5 : 101.

25. wei xiao, zenghui he, meijian sun, shiliang li, honglin li*. statistical analysis, investigation and prediction of the water positions in the binding sites of proteins. j. chem. inf. model., 2017. 57(7) : 1517-1528.

26. jun yuan^#, ye zhong^#, shiliang li, xue zhao, guoqin luan, zhenjiang zhao, jin huang*, honglin li*, yufang xu*. triazole and benzotrizaole derivatives as novel inhibitors for p90 ribosomal s6 protein kinase 2: synthesis, molecular docking and sar analysis. chin. j. chem., 2013. 31(9) : 1192-1198.

27. jiawei wang, yanyan diao, junsheng zhu, shiliang li, zhenjiang zhao, honglin li*, lili zhu*. biological evaluation of quinoline derivatives as inhibitors of human dihydroorotate dehydrogenase. med. chem. commun. 2016, 7, 853-858..

28. junsheng zhu^#, le han^#, yanyan diao^#, xiaoli ren, minghao xu, liuxin xu, shiliang li, qiang li, dong dong, jin huang, xiaofeng liu, zhenjiang zhao, rui wang, lili zhu*, yufang xu, xuhong qian*, honglin li*. design, synthesis, x-ray crystallographic analysis, and biological evaluation of thiazole-derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase. j. med. chem., 2015. 58 : 1123-1139.

29. tianfeng xu, lianwen zhang, shilin xu, chaoyie yang, jinfeng luo, fang ding, xiaoyun lu, yinxue liu, zhengchao tu, shiliang li, duanqing pei, qian cai, honglin li, xiaomei ren, shaomeng wang, ke ding. pyrimido[4,5-d]pyrimidin-4(1h)-one derivatives as selective inhibitors of egfr threonine790 to methionine790 (t790m) mutants. angew. chem. int. ed. engl., 2013. 125 (32) : 8545-8548.

30. xia wang, haipeng chen, feng yang, jiayu gong, shiliang li, jianfeng pei*, xiaofeng liu*, hualiang jiang, luhua lai, honglin li*. idrug: a web-accessible and interactive drug discovery and design platform. j. cheminform., 2014. 6: 28.

31. shoude zhang, lei shan, qiao li, xia wang, shiliang li, yuan zhang, jianjun fu, xiaofeng liu, honglin li*, weidong zhang*. systematic analysis of the multiple bioactivities of green tea through a network pharmacology approach. evid. based complement. alternat. med., 2014. 2014 : 512081.